The Effect of Diabetes Mellitus on the Prognosis of Patients With COVID-19

Diabetes Mellitus Clinical Trial

— COVID-19-DM2  

Official title:

The Effect of Diabetes Mellitus on the Morbidity and Mortality Rates in Patients With COVID-19

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04591704
• Other study ID #: UU-DM003
• Status: Recruiting
• Start date: March 20, 2020
• Est. completion date: July 1, 2021

Study information

• Verified date: May 2021
• Source: Usak University
• Contact: Cevdet Duran
• Phone: 02762212121
• Email: drcduran[@]gmail.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

All hospitalised patients with COVID-19 who have positive RT-PCR for SARS-COV-2 will be included in the study.

The patients will be divided into two groups, as diabetics and non-diabetics. The COVID-19 patients' medical records will be evaluated and compared in terms of the duration of hospitalization, the presence of lung involvement in Computerised Tomography, the need for intensive care unit and mortality rates in patients with and without diabetes.

Description:

All hospitalised patients with COVID-19 who have positive RT-PCR for SARS-COV-2 will be included in the study.

The patients will be divided into two groups, as diabetics and non-diabetics. The diagnosis of diabetes mellitus will be extracted from the medical records and medical history of the patients hospitalised with COVID-19.

The COVID-19 patients medical records will be evaluated and compared in terms of the duration of hospitalization, the presence of lung involvement in Computerised Tomography, the need for intensive care unit and mortality rates in patients with and without diabetes.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 2000
• Est. completion date: July 1, 2021
• Est. primary completion date: October 15, 2020
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Patients hospitalized for COVID-19

Exclusion Criteria:

• Patients with known malignancy

• Pregnant patients

Related Conditions & MeSH terms

• Covid19
• Diabetes Mellitus

Intervention

Other:
• hospitalisation, necessity of ICU, mortality rate, lung involvement
hospitalisation, necessity of ICU, mortality rate, lung involvement

Locations

Country	Name	City	State
Turkey	Usak University Training and Research Hospital	Usak

Sponsors (1)

Lead Sponsor	Collaborator
Usak University

Country where clinical trial is conducted

Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Duration of Hospitalisation	The time between admission to hospital and discharge	1 year
Primary	The need for ICU	The admission of hospitalized patients to the intensive care unit.	1 year
Primary	Mortality	Mortality rates of patients	1 year
Primary	Lung involvement	The presence of lung involvement on thorax CT	1 year